CLOPIDOGREL
Cerebral Infarction
The Second Hospital of Anhui Medical UniversitySmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 68/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the Cerebral Infarction cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril Asan Medical Center | Phase 4 | BBB |
Acetylsalicylic Acid Sclnow Biotechnology Co., Ltd. | Phase 4 | BBB |
Sovateltide Pharmazz, Inc. | Phase 4 | BBB |
Human Urinary Kallidinogenase Huisheng Chen | Phase 4 | BB |
Hua Tuo Zai Zao Wan Guangzhou University of Traditional Chinese Medicine | Phase 4 | BB |
View all 49 →
Same molecule, other indications
CLOPIDOGREL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →